FDA Under Crawford: Risk Assessment Would Be Important Theme
Executive Summary
FDA's backlog of 51 pending "approvable" NDAs and supplemental NDAs will provide one quantifiable marker to use in measuring the impact of a commissioner appointment.
You may also be interested in...
HHS Bioterrorism Appointment Could Reduce Pressure For FDA Nominee
The appointment of Donald Henderson, MD, to head the HHS Office of Public Health Preparedness could reduce some of the pressure on the Bush Administration to move quickly on a nomination for an FDA commissioner
HHS Bioterrorism Appointment Could Reduce Pressure For FDA Nominee
The appointment of Donald Henderson, MD, to head the HHS Office of Public Health Preparedness could reduce some of the pressure on the Bush Administration to move quickly on a nomination for an FDA commissioner
Genzyme Renagel Trial Will Compare Effect On Mortality With Other Agents
Genzyme is studying Renagel's effect on cardiac calcification and mortality to support a comparative claim versus other phosphate binders, Genzyme Senior VP-Corporate Affairs Elliott Hillback told the Bear Stearns "virtual" healthcare conference Sept. 24.